Related references
Note: Only part of the references are listed.Anidulafungin: advantage for the newcomer?
Maria J Rüping et al.
Expert Review of Clinical Pharmacology (2008)
Synthesis of the antifungal β-1,3-glucan synthase inhibitor CANCIDAS (caspofungin acetate) from pneumocandin B0
William R. Leonard et al.
JOURNAL OF ORGANIC CHEMISTRY (2007)
Invasive fungal pathogens: Current epidemiological trends
Michael A. Pfaller et al.
CLINICAL INFECTIOUS DISEASES (2006)
Normal phase high-performance liquid chromatography of pneumocandins:: In situ modification of silica with L-proline to separate structural analogues
J Nti-Gyabaah et al.
BIOTECHNOLOGY PROGRESS (2006)
Influence of mobile phase composition and thermodynamics on the normal phase chromatography of echinocandins
DJ Roush et al.
JOURNAL OF CHROMATOGRAPHY A (2005)
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy
J Maertens et al.
CLINICAL INFECTIOUS DISEASES (2004)
Comparison of caspofungin and amphotericin B for invasive candidiasis.
J Mora-Duarte et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Determination of the relative and absolute configuration of the dimethylmyristoyl side chain of pneumocandin B0 by asymmetric synthesis
WR Leonard et al.
ORGANIC LETTERS (2002)
Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients
KA Marr et al.
CLINICAL INFECTIOUS DISEASES (2002)
Randomized, double-blind, Multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases
EG Arathoon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus
S Ascioglu et al.
CLINICAL INFECTIOUS DISEASES (2002)
Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices
N Singh
CLINICAL INFECTIOUS DISEASES (2001)
A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis
A Villanueva et al.
CLINICAL INFECTIOUS DISEASES (2001)
Aspergillosis case - Fatality rate: Systematic review of the literature
SJ Lin et al.
CLINICAL INFECTIOUS DISEASES (2001)
Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice
GK Abruzzo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Invasive aspergillosis - Disease spectrum, treatment practices, and outcomes
TF Patterson et al.
MEDICINE (2000)
Practice guidelines for the treatment of candidiasis
JH Rex et al.
CLINICAL INFECTIOUS DISEASES (2000)
Epidemiology of human immunodeficiency virus-associated opportunistic infect-ions in the United States in the era of highly active antiretroviral therapy
JE Kaplan et al.
CLINICAL INFECTIOUS DISEASES (2000)
Share Paper
